听力损失与突发性聋预后的关系

目的:探索听力损失对突发性聋预后的影响。方法:对146例(167耳)突聋患者的临床资料进行回顾性分析,应用SAS统计软件对纯音听阈情况与预后的关系进行统计学处理。结果:单因素分析显示,初诊时听力损失曲线为全聋型,纯音高频听阈(4 000 Hz及8 000 Hz)损失较重,高频听阈(4 000 Hz+8 000 Hz)大于低频(250 Hz+500 Hz)听阈的患者预后不佳;多因素分析显示,8 000 Hz的听阈水平与预后关系最为密切,其次为4 000 Hz听阈及听力损失类型。结论:从单、多因素分析的结果可以看出,对突聋应采用多因素逐步分析的方法进行研究,以使预后和疗效评估更具准确性和客观性;高频听力损失程度是突发性聋预后的一个可靠评估因素。     

Sudden (reversible) sensorineural hearing loss in pregnancy

Background  

Sudden hearing loss directly associated with pregnancy or birth is a little known and rare occurrence. The temporary, unilateral, low-frequency sensorineural hearing loss in this case was reported after the birth of the patient’s first child, and again during the third trimester of her second pregnancy.     

Sudden death in a patient with chronic lymphocytic leukemia

The authors describe a 51-year-old man with chronic lymphocytic leukemia who presented with respiratory distress and then died suddenly while in hospital. Autopsy revealed pulmonary leukostasis and a large intracardiac mass containing mostly mature lymphocytes and fibrin. Although leukostasis and lymphocyte thrombi have been described (albeit rarely) in chronic lymphocytic leukemia, an intracardiac "clot" has not. It seems plausible that this intracardiac mass caused the patient's death.     

Leukemic synovitis as a presentation of myelomonocytic blast crisis of chronic myeloid leukemia

We describe a patient with a 2-month history of right shoulder monoarthritis and fever as the presenting symptoms of a subsequent diagnosis of chronic myeloid leukemia in blast crisis. Imaging studies showed changes consistent with leukemic infiltration of the soft tissues around the right shoulder joint and the proximal humerus. Immunophenotypic and morphologic analysis of the large number of cells obtained from the synovial fluid confirmed the shoulder synovitis to be an extramedullary manifestation of myelomonocytic blast crisis of chronic myeloid leukemia. The patient was not a candidate for aggressive chemotherapy treatment because of her poor overall condition, and she had no compatible donor for allogenic bone marrow transplantation. Her painful arthropathy was refractory to standard pain management but she achieved excellent pain relief with palliative radiation therapy. We conclude that the involvement of extramedullary sites by chronic myeloid leukemia blast cells can predate hematological blast crisis in some of chronic myeloid leukemia cases. Also, painful leukemic synovitis can be managed by low dose radiotherapy in a candidate who is refractory to chemotherapy and other medical therapy.     

慢性粒细胞白血病的生物治疗

慢性粒细胞白血病(CML)是一种造血干细胞的恶性克隆增殖性疾病,以分子生物学、免疫学为基础的生物治疗手段成为新的研究方向.生物治疗主要包括分子靶向治疗、基因治疗和过继免疫治疗.基因治疗主要通过基因转染使肿瘤细胞抗原标志过度表达而增加机体的免疫识别;或通过下调相关原癌基因表达,抑制细胞增殖,诱导细胞凋亡等方式发挥抗肿瘤作用.过继免疫治疗是将CIK、NK等免疫活性细胞注入肿瘤宿主体内的一种治疗方法.基于K562细胞系的相关研究为深入进行生物治疗研究奠定了基础,但因缺乏合适靶标等原因,生物治疗尚不能取代传统的治疗方法.     

Neoplastic pericarditis as the initial manifestation of a papillary thyroid carcinoma

Abstract

Neoplastic pericarditis represents approximately 5%–7% of the cases with acute pericarditis and is rarely the initial manifestation of malignancy. The most common cause is lung cancer, followed by breast cancer, lymphomas, leukemia, and esophageal cancer. Neoplastic pericardial disease is extremely rare in thyroid cancer, especially as the first manifestation. Here, we present a papillary thyroid carcinoma that was manifested with pericarditis and cardiac tamponade in a 49-year-old female.     

以布加综合征为初始表现的儿童急性早幼粒细胞白血病1例及文献复习

日的探讨左炔谐孕關宫内缓释系统对子宫腺肌病痛經患者卵巢功能及神经生长因子(NCF).转化生长园于(TCF)-BI表达的影响。方法 选取2018年1月至200年5月大连市妇女儿童医疗中心(集团)收治的90例子宫腺肌病患者分为既察组与对照组各45例。对照组給予常规治疗。觀察姐給予常规治疗联合左炔谐孕關宫内缓释系境治疗。比校两组治疗前后于宫内膜厚度.两组治疗不同时间点的VAS评分.两组治疗前后血清CA125含量及两组治疗前后血清NCF.ICF-B1含量。结果两组治疗后的于宫内膜厚度(7.1441 02)mm和(943185)mm]低于治疗前(129138)mm (和(127484.15 ))0000)观察组低于对關(.141.02)mm .09.341.858am(P0.05)。脱察组治疗第1 41(月(4.140.21)分:(62420171)51.2 (月(.040.15)分+50.42)分01.3个月(151044)分) n(2 87127)分]的痛经VAs评分低于对照组Pc[J].0)。两组治疗后的血清CA125值(1184+489)x10W/.和(31 673.81)01PU/LJ低f治疗(724-3387)x10/07(102848)109/L(0.01),.观察组低于对照组(11.844 9)x10U/L姓(31 851)10101000)00)两组治疗后的血清NGF.TGF-B1古量高于治护(前(PC0.01),现实组高于对關(0001)。铺论左炔谐孕闡宫内鏝释系统在于宫腺肌病患者的应用能缓解南經程度,改善患者的卵巢功能,抑制NCF .TCF-B1 的释放,减少子宫内膜厚度。     

Hematopoietic stem cells in chronic myeloid leukemia

Chronic myeloid leukemia (CML) is a malignant myeloproliferative disorder originating from a pluripotent hematopoietic stem cell that acquires a Philadelphia (Ph) chromosome encoding the BCR-ABL oncogenic fusion protein. This molecular abnormality that is thought to be causative in CML was the first acquired chromosome translocation associated with a human malignancy. This chromosomal translocation also makes it possible to precisely distinguish between residual normal (i.e., Ph-, BCR-ABL-) progenitor or stem cells and their leukemic counterpart, Ph+ or BCR-ABL+ progenitor/stem cells in every given sample of a patient with CML. This has provided seminal insights into the molecular and cellular biology of leukemia and also of the process of normal hematopoiesis. CML has become a fascinating model disease for malignancy in general.     

慢性淋巴细胞性白血病合并慢性髓细胞性白血病一例报告

1临床资料患者,男性,48岁,因“确诊慢性淋巴细胞性白血病(CLL)8年余,确诊慢性髓细胞性白血病(CML)2年余“入院.……     

甲磺酸伊马替尼治疗慢性粒细胞白血病疗效观察

目的探讨甲磺酸伊马替尼治疗慢性粒细胞白血病（CML）的体会。方法40例CML患者接受甲磺酸伊马替尼治疗,其中慢性期（CP）20例,加速期（AP）8例,急变期（BC）12例。甲磺酸伊马替尼用法：CP患者400mg/d,AP和BC患者600mg/d,均为餐后1次顿服。治疗前全面查体,查血象、骨髓象、Ph染色体和（或）bcr／abl融合基因。治疗期间第1个月每周查血象2次,1个月后每周或2周1次。每2～4周查一次肝、肾功能。待血液学取得完全缓解（CR）后择期复查骨髓、Ph染色体和（或）bcr／abl基因。根据血象和患者对药物耐受情况及时调整药物剂量。结果经中位时间20个月（12～24个月）随访,20倒CMLCP期患者均取得血液学CR,其中7例（35％）Ph染色体转阴,8例AP患者中6例（75％）回到CP,12例BC患者中4例（33．3％）回到CP。药物不良反应有造血功能抑制、眶周和下肢轻度水肿、全身肌肉关节酸痛和恶心、呕吐、低热（37．5～38．5℃）、皮疹、胆红素升高等。结论甲磺酸伊马替尼对CML有较好疗效,药物不良反应可耐受。     

Imatinib mesylate in the treatment of chronic myeloid leukemia: a local experience

This study was done to assess the overall response rate of imatinib mesylate in local patients with chronic myeloid leukaemia. A total of 69 patients were recruited with male/female ratio of 7:3. Of the 69 patients; 35% were in the chronic phase, 41% were in the accelerated phase, 17% were in blast crisis and the remaining 7% were after stem cell transplantation. Complete haematological response rates of patients in chronic phase, accelerated phase and blast crisis were 95.8%, 96.4% and 41.7% respectively. Thirty-eight percent of patients achieved complete cytogenetic response and 10% achieved partial cytogenetic response. The cytogenetic response rates were 80%, 41.7% and 18.2% in chronic, accelerated and blast crisis phase respectively (p < 0.005). Twenty-six percent of patients developed anaemia, 13% had neutropenia and 12% had thrombocytopenia after starting on treatment. In addition, 14% of patients developed peripheral oedema, 13% complained of musculoskeletal pain, 12% had gastrointestinal side effects which include nausea, vomiting and diarrhoea, 9% had grade 1 hepatotoxicity, 7% developed skin rashes and one patient had an abnormal renal function test. Patients taking 600mg or higher dosage of imatinib had more gastrointestinal side effects. Patients who weighed less than 60kg had a much higher risk of developing anaemia. Anaemia was a negative predictor of cytogenetic response. Presenting high white blood cell counts and absence of cytogenetic response were also negative predictors of survival. Overall survival was 87%. This was affected by the different phases of disease (chronic phase was better than accelerated and blast crisis) (p < 0.001). In conclusion, our local CML patients did well on treatment with imatinib.     

尼洛替尼和伊马替尼一线治疗慢性髓性白血病的疗效及安全性观察

目的:比较尼洛替尼和伊马替尼一线治疗初诊慢性髓性白血病(chronic myeloid leukemia,CML)慢性期(chronic phase,CP)患者的疗效和安全性?方法:65例新诊断的CML-CP患者,接受口服尼洛替尼300~400 mg,每日2次(尼洛替尼组)或口服伊马替尼400 mg,每日1次(伊马替尼组)治疗,比较两组患者的疗效及安全性?结果:65例初发CML-CP患者,确诊CML的中位时间均为19.5(5~39)个月?尼洛替尼组26例,伊马替尼组39例,治疗后3?6?12个月时尼洛替尼组主要分子学反应(major mdecular response,MMR)获得率高于伊马替尼组,分别为23.1% vs. 7.6%?45.5% vs. 21.2%?66.7% vs. 54.8%,且在6个月时有显著差异?Sokal积分低?中和高危组患者12个月MMR的获得率在尼洛替尼组和伊马替尼组分别为81.3% vs. 42.8%?42.8% vs. 57.1%?66.7% vs. 50.0%?3个月获得Bcr-Abl ≤ 10%的发生率在尼洛替尼组为80.8%,显著高于伊马替尼组的41.0%;6个月达Bcr-Abl<1%的比例在尼洛替尼组为77.3%,高于伊马替尼组的48.5%,均有显著差异?12个月Bcr-Abl<0.1%的比例在尼洛替尼组为66.7%,高于伊马替尼组的54.8%,尼洛替尼组达MMR的中位时间短于伊马替尼组(14 vs. 34个月)?尼洛替尼组和伊马替尼组3?6和12个月获得细胞遗传学缓解(complete cytogenetic rewsponse,CCyR)的比例分别为76.9% vs.52.9%?89.5% vs. 70.0%?78.5% vs. 77.3%,达CCyR的中位时间分别为3个月和 6个月?尼洛替尼和伊马替尼组治疗相关的不良反应多为1~2级,患者大多可耐受?结论:尼洛替尼治疗初诊CML-CP较伊马替尼更早达到分子学缓解,安全有效,有可能作为一线用药?     

以胸腔积液为主要表现的急性淋巴细胞白血病1例

患者男,１９岁,因咳嗽、盗汗２月,加重伴气促５ ｄ于 １９９９年９月２２日入院。２月前患者无明显诱因出现咳嗽,干咳,夜间为甚,盗汗,院外治疗效果差,并出现咳嗽加剧,胸闷、气促。颜面水肿。胸片及Ｂ超检查：胸腔积液、心包积液。血常规正常（院外医生告诉患者）,具体不详（未见到检查结果）。予以抗炎、抽液治疗后症状仍无减轻而入我院。查体：Ｔ３７．８℃,Ｐ １１０次ｍｉｎ,Ｒ ２２次／ｍｉｎ,ＢＰ １４．５／11．０ ｋＰａ,气管左偏,右侧胸廓饱满,呼吸动度减弱,中下部语颤减弱,叩诊实音,呼吸音低。心浊音界向两侧扩…     

慢性粒细胞白血病干细胞microRNA的表达

目的 通过比较慢性粒细胞白血病(CML)患者骨髓的白血病干细胞(LSC)和健康人骨髓正常造血干细胞(HSC)的microRNA (miRNA)表达谱,鉴定在CML LSC表达异常的miRNAs.方法 通过磁珠法分选获得分子表型为CD34+ CD38-的CML LSC和正常HSC.使用Exiqon人miRNA芯片检测miRNA的表达情况.选取差异表达的miRNAs进行qRT-PCR验证.结果 利用Exiqon人miRNA芯片一共检测了1 900个人源miRNAs的表达情况.其中1个miRNA在CML LSC中发生显著的表达上调,46个miRNAs发生显著的表达下调.基于KEGG的pathway显著性分析显示,CML LSC表达下调的miRNAs参与的显著性信号转导通路是神经营养因子信号通路.qRT-PCR检测miR-584-5p、miR-675-3p和miR-431-5p的表达情况与miRNA芯片检测结果一致.结论 鉴定了在人CML LSC中表达异常的miRNAs,为miRNA在CML LSC中的潜在应用奠定基础.